<format type="yaml">{report_id: string, report_date: date, patient_details: {patient_id: string, age_at_reaction: number optional, gender: string, relevant_history: list[string]}, suspected_drugs: list[{drug_name: string, drug_class: string optional, dosage: string, route_of_administration: string, start_date: date, end_date: date optional, indication_for_use: string}], adverse_reactions: list[{symptom_name: string, onset_date: date, severity: string, outcome: string, intervention_required: boolean, intervention_details: string optional}], causality_assessment: {naranjo_score: number optional, assessment_conclusion: string, dechallenge_rechallenge: string}, reporting_facility: string, reporter_type: string, notes: string optional}</format> <data>PHARMACOVIGILANCE CASE REPORT - CONFIDENTIAL
Report Identifier: ADR-2025-405
Date of Submission: 2025-06-16

This report was submitted by a Pharmacist from Hubbard Inc Medical Center concerning patient ANON-PX-5242. The subject is a 58-year-old male with a significant medical history including asthma, anxiety, chronic kidney disease. The facility's standard operating procedure for ADR reporting was followed, and all patient data has been anonymized. The patient chart was reviewed for comorbidities. 

Current medication review revealed the following suspected agent(s): Lisinopril administered via the Intravenous route at a dosage of 462mg, initiated on 2025-04-17 for Hypertension and discontinued on 2025-06-12.

On approximately 2025-06-08, the patient began to manifest an adverse event. The primary symptoms noted in the clinical log were Dizziness, Somnolence. The Dizziness was classified as Moderate in severity. This necessitated clinical intervention. The current patient status regarding this symptom is 'Not Recovered'. The Somnolence was classified as Severe in severity. This necessitated clinical intervention. The current patient status regarding this symptom is 'Unknown'. 

CAUSALITY ASSESSMENT:
An evaluation of causality was performed. The assessment concluded the relationship was 'Probable'. Dechallenge/Rechallenge status was noted as: 'Positive rechallenge'. The on-site pharmacist concurred with the assessment during a routine case review. 

</data>
report_id: ADR-2025-405
report_date: '2025-06-16'
patient_details:
  patient_id: ANON-PX-5242
  gender: Male
  relevant_history:
  - asthma
  - anxiety
  - chronic kidney disease
  age_at_reaction: 58
suspected_drugs:
- drug_name: Lisinopril
  dosage: 462mg
  route_of_administration: Intravenous
  start_date: '2025-04-17'
  indication_for_use: Hypertension
  end_date: '2025-06-12'
adverse_reactions:
- symptom_name: Dizziness
  onset_date: '2025-06-08'
  severity: Moderate
  outcome: Not Recovered
  intervention_required: true
- symptom_name: Somnolence
  onset_date: '2025-06-08'
  severity: Severe
  outcome: Unknown
  intervention_required: true
causality_assessment:
  assessment_conclusion: Probable
  dechallenge_rechallenge: Positive rechallenge
reporting_facility: Hubbard Inc Medical Center
reporter_type: Pharmacist
